Takeda Pharmaceutical Company raised its full-year earnings forecast for the fiscal year ending March 2027. Reflecting the expansion of overseas earnings against a weaker yen, it raised its forecasts for revenue and operating profit.
Takeda Pharmaceutical Company raised its full-year consolidated earnings forecast for the fiscal year ending March 2027. It newly disclosed its outlook based on International Financial Reporting Standards (IFRS).
In the revision, both revenue and operating profit were raised, reflecting the expansion of overseas earnings amid the weaker yen. Profitability in the overseas business appears to have improved, mainly in Europe and the United States.
Market exchange-rate trends and growth in the overseas business were cited as factors behind the revision. Takeda Pharmaceutical may view a period of yen depreciation as a factor supporting expansion in overseas markets.
The revision is positioned as an important update affecting the company's full-year plan. Future earnings trends and the impact of exchange rates will be key areas of focus.